LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.76
+4.55%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.65
From 52W high−74.04%
Volume1.86M
Market cap$226.45M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.65
From 52W high
−74.04%
Volume
1.86M
Market cap
$226.45M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
27.6
MomentumView details →
1D Return
+4.55%
YTD Return
−72.96%
SummaryUpdated Jun 1, 2026
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company founded in 2017 and headquartered in New York, New York. The company went public in November 2023 and focuses on developing gene therapies for both hereditary and acquired diseases. Lexeo operates in the biotechnology sector, specifically targeting genetic disorders through advanced gene therapy approaches using adeno-associated virus (AAV) vectors.
Similar companies
Latest newsMore news →
Lexeo Therapeutics announced that an abstract on its LX2006 gene therapy has been accepted for oral presentation at the International Congress of Parkinson's Disease and Movement Disorders 2026, to be held October 4-8, 2026 in Seoul, Korea.18d agoLexeo Therapeutics completed its acquisition of Mantle Therapeutics through a merger of its subsidiary Magma Merger Sub with and into Mantle, with upfront consideration of $5.3 million in cash and $3.0 million in Lexeo common stock plus up to $1.0 million in additional cash and $12.0 million in milestone payments.20d agoKey Stockholders holding approximately 76.1% of Mantle Therapeutics' outstanding capital stock agreed to vote their shares in favor of the Lexeo Therapeutics merger.27d ago